Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension

Sean Gaine, Kelly Chin, Gerry Coghlan, Richard Channick, Lilla Di Scala, Nazzareno Galiè, Hossein-Ardeschir Ghofrani, Irene M Lang, Vallerie McLaughlin, Ralph Preiss, Lewis J Rubin, Gérald Simonneau, Olivier Sitbon, Victor F Tapson, Marius M Hoeper, Sean Gaine, Kelly Chin, Gerry Coghlan, Richard Channick, Lilla Di Scala, Nazzareno Galiè, Hossein-Ardeschir Ghofrani, Irene M Lang, Vallerie McLaughlin, Ralph Preiss, Lewis J Rubin, Gérald Simonneau, Olivier Sitbon, Victor F Tapson, Marius M Hoeper

Abstract

Patients with connective tissue disease-associated pulmonary arterial hypertension (PAH-CTD) have a poor prognosis compared with other aetiologies. The underlying CTD can influence treatment response and outcomes. We characterised the GRIPHON study PAH-CTD subgroup and evaluated response to selexipag.Of 334 patients with PAH-CTD, PAH was associated with systemic sclerosis (PAH-SSc) in 170, systemic lupus erythematosus (PAH-SLE) in 82 and mixed CTD/CTD-other in 82. For the primary composite endpoint of morbidity/mortality, hazard ratios (HR) and 95% CI were calculated using Cox proportional hazard models.Compared with the overall GRIPHON population, the CTD subgroup was slightly older with a greater proportion of females and shorter time since diagnosis. Patients with PAH-SSc appeared to be more impaired at baseline, with a more progressive disease course. The converse was observed for PAH-SLE. Selexipag reduced the risk of composite morbidity/mortality events in patients with PAH-CTD by 41% (HR 0.59; 95% CI 0.41-0.85). Treatment effect was consistent irrespective of baseline PAH therapy or CTD subtype (interaction p=0.87 and 0.89, respectively). Adverse events were predominately prostacyclin-related and known for selexipag treatment.GRIPHON has allowed the comprehensive characterisation of patients with PAH-CTD. Selexipag delayed progression of PAH and was well-tolerated among PAH-CTD patients, including those with PAH-SSc and PAH-SLE.

Trial registration: ClinicalTrials.gov NCT01106014.

Conflict of interest statement

Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

Copyright ©ERS 2017.

Figures

FIGURE 1
FIGURE 1
Effect of selexipag on the primary composite endpoint of morbidity/mortality by pulmonary arterial hypertension (PAH) therapy at baseline and connective tissue disease (CTD) subtype. ERA: endothelin receptor antagonist; PDE-5i: phosphodiesterase type-5 inhibitor; SSc: systemic sclerosis; SLE: systemic lupus erythematosus; MCTD: mixed CTD.
FIGURE 2
FIGURE 2
Effect of selexipag on the primary composite endpoint of morbidity/mortality in patients with a) pulmonary arterial hypertension associated with systemic sclerosis and b) pulmonary arterial hypertension associated with systemic lupus erythematosus.

References

    1. Mathai SC, Hassoun PM. Pulmonary arterial hypertension in connective tissue diseases. Heart Fail Clin 2012; 8: 413–425.
    1. McLaughlin V, Humbert M, Coghlan G, et al. . Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford) 2009; 48: Suppl. 3, iii25–iii31.
    1. Humbert M, Sitbon O, Chaouat A, et al. . Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023–1030.
    1. Kähler CM, Colleselli D. Pulmonary arterial hypertension (PAH) in connective tissue diseases. Rheumatology (Oxford) 2006; 45: Suppl. 3, iii11–iii13.
    1. Rhee RL, Gabler NB, Sangani S, et al. . Comparison of treatment response in idiopathic and connective tissue disease-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2015; 192: 1111–1117.
    1. Johnson SR, Granton JT. Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus. Eur Respir Rev 2011; 20: 277–286.
    1. Distler O, Pignone A. Pulmonary arterial hypertension and rheumatic diseases – from diagnosis to treatment. Rheumatology (Oxford) 2006; 45: Suppl. 4, iv22–iv25.
    1. Pulido T, Adzerikho I, Channick R, et al. . Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809–818.
    1. Coghlan JG, Galie N, Barbera JA, et al. . Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis 2017; 76: 1219–1227.
    1. Sitbon O, Channick R, Chin KM, et al. . Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015; 373: 2522–2533.
    1. Condliffe R, Howard LS. Connective tissue disease-associated pulmonary arterial hypertension. F1000Prime Rep 2015; 7: 6.
    1. Condliffe R, Kiely DG, Peacock AJ, et al. . Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151–157.
    1. Schreiber BE, Connolly MJ, Coghlan JG. Pulmonary hypertension in systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2013; 27: 425–434.
    1. Farber HW, Miller DP, Poms AD, et al. . Five-year outcomes of patients enrolled in the REVEAL Registry. Chest 2015; 148: 1043–1054.
    1. Chung L, Liu J, Parsons L, et al. . Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138: 1383–1394.
    1. Avouac J, Wipff J, Kahan A, et al. . Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials. Ann Rheum Dis 2008; 67: 808–814.
    1. Rubin LJ, Badesch DB, Barst RJ, et al. . Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896–903.
    1. Ramjug S, Hussain N, Hurdman J, et al. . Long-term outcomes of domiciliary intravenous iloprost in idiopathic and connective tissue disease-associated pulmonary arterial hypertension. Respirology 2017; 22: 372–377.
    1. Humbert M, Coghlan JG, Ghofrani HA, et al. . Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis 2017; 76: 422–426.
    1. Mathai SC, Girgis RE, Fisher MR, et al. . Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 2007; 29: 469–475.
    1. European Medicines Agency. European Public Assessment Report: Uptravi (selexipag) 2016. Date last accessed: March 15, 2017. Date last updated: April 1, 2016.
    1. Savarese G, Paolillo S, Costanzo P, et al. . Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012; 60: 1192–1201.
    1. Farber HW, Miller DP, McGoon MD, et al. . Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. J Heart Lung Transplant 2015; 34: 362–368.
    1. Rhee RL, Gabler NB, Praestgaard A, et al. . Adverse events in connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheumatol 2015; 67: 2457–2465.
    1. Tapson VF, Jing ZC, Xu KF, et al. . Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest 2013; 144: 952–958.
    1. Jing ZC, Parikh K, Pulido T, et al. . Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized controlled trial. Circulation 2013; 127: 624–633.
    1. Tapson VF, Torres F, Kermeen F, et al. . Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (The FREEDOM-C Study): a randomized controlled trial. Chest 2012; 142: 1383–1390.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren